Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Rockwell Medical, Inc., incorporated in the state of Michigan in 1996, is a fully-integrated biopharmaceutical company targeting end-stage renal disease ("ESRD") and chronic kidney disease ("CKD") with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis (also referred to as "HD" or "dialysis"). Rockwell's lead investigational drug is in late stage clinical development for iron therapy treatment in CKD-HD patients. It is called Soluble Ferric Pyrophosphate ("SFP"). SFP delivers iron to the bone marrow in a non-invasive, physiologic manner to hemodialysis patients via dialysate during their regular dialysis treatment. The majority of ESRD patients receive iron on a routine basis. The Company intends to complete clinical trials and seek U.S. Food and Drug Administration ("FDA") market approval of SFP. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.65 |
| Quarterly EPS Est: | -0.31 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research
